Patent intelligence · US
US 10206886
Lipid nanoparticles for wound healing
Lipid nanoparticles for wound healing
Patent details — US 10206886
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 19, 2019
- Expiration
- Feb 14, 2039
- Applicant
- PRAXIS BIOPHARMA RESEARCH INSTITUTE
- Claims
- 17
- CPC classes
- A61K, A61K38/1729, A61K38/18, A61K38/1808
Quick answer
US 10206886 (Lipid nanoparticles for wound healing) is held by PRAXIS BIOPHARMA RESEARCH INSTITUTE. Status: granted. Granted Feb 19, 2019. Expires Feb 14, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PRAXIS BIOPHARMA RESEARCH INSTITUTE
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K38/1729, A61K38/18, A61K38/1808, A61K9/5123, A61K9/5192
More from PRAXIS BIOPHARMA RESEARCH INSTITUTE
Related pharmaceutical patents in our USPTO index.
-
US 12404297
Salts and crystal forms of GABA-A positive allosteric modulator
granted -
US 12325711
3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-α]pyrazine as an ion channel modulator
granted -
US 12259378
Dynamic clamps and methods of use thereof
granted -
US 12145939
Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
granted -
US 12077502
Formulations of T-type calcium channel modulators and methods of use thereof
granted -
US 11918571
Compounds and their methods of use
granted -
US 11919836
Prodrugs of fencamfamine
granted -
US 11866439
Ion channel modulators
granted
Frequently asked questions
What is US patent 10206886?
US 10206886 (Lipid nanoparticles for wound healing) is held by PRAXIS BIOPHARMA RESEARCH INSTITUTE. Status: granted. Granted Feb 19, 2019. Expires Feb 14, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10206886?
PRAXIS BIOPHARMA RESEARCH INSTITUTE is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 10206886 expire?
Our index shows an expiration date of Feb 14, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.